| Eligibility |
Inclusion Criteria:
1. Written and signed informed consent
2. Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1
3. Histologically confirmed classic Hodgkin's lymphoma (cHL) (based on tumor tissue
obtained within 3 years prior to enrollment).
4. Relapsed (disease progression during or after most recent therapy) or refractory
(failure to achieve CR or PR after most recent therapy) cHL and meet any of the
following criterions:
1. Recurrence or disease progression after autologous hematopoietic stem cell
transplantation.
2. For subject without receiving , the subject has received at least 2 lines of
prior systemic chemotherapy. Refractory subject is defined as subject who has not
achieved PR after at least 2 cycles of treatment, or subject who has not achieved
CR after at least 4 cycles of treatment. If the best response to treatment is PD
or the reason for ending the treatment is PD, the subject is consider as
refractory without requirement on the number of cycles of treatment that the
subject has received. For relapsed subjects, disease progression occurred for the
subject who has received at least 2 line of prior systemic chemotherapy.
5. Subject must have at least one measurable lesion (> 1.5 cm in the longest diameter, or
> 1 cm in the longest diameter with uptake on 18FDG-PET)according to the Lugano 2014
criteria.
6. Adequate organ functions.
7. Use effective methods of contraception.
Exclusion Criteria:
1. Known nodular lymphoma predominant Hodgkin lymphoma or Grey zone lymphoma.
2. Lymphoma involving the central nervous system.
3. Participated in other clinical studies of experimental drugs or received research
treatment or used experimental equipment within 4 weeks prior to the first dose of
AK105.
4. Concurrent enrollment in another clinical study, unless it is an observational
(non-interventional) clinical study or the follow-up period of an interventional
study.
5. Receipt of the last radiotherapy or the last dose of anticancer therapy (chemotherapy,
target therapy, immunotherapy or tumor embolism, etc.) with 4 weeks prior to the first
dose of AK105. Receipt of the last dose of nitrocarbamide or mitomycin C within 6
weeks prior to the first dose of AK105.
6. Prior exposure to any anti-PD-1, anti-PD-L1, anti-CTL4 antibody or any other antibody
or drug targeting T-cell costimulation or checkpoint pathways such as ICOS, or
agonists such as CD40, CD137, GITR, OX40 etc..
7. Had other active malignancies within 5 years prior to enrollment. Locally curable
cancer (manifested as cured) is excluded, such as basal or cutaneous squamous cell
carcinoma, superficial bladder cancer, cervical or breast carcinoma in situ.
8. Active, known or suspected autoimmune diseases, or a history of the disease within the
past 2 years, except the following: vitiligo, alopecia, Graves' disease, psoriasis or
eczema that do not require systemic treatment within the last 2 years, hypothyroidism
(caused by autoimmune thyroiditis) only requiring a stable dose of hormone replacement
therapy, type I diabetes requiring only a stable dose of insulin replacement therapy,
or diseases not expected to recur in the absence of external triggering factors.
9. Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative
colitis or chronic diarrhea).
10. Subjects with a condition requiring systemic treatment with either corticosteroid (>
10 mg daily prednisone equivalents) or other immunosuppressive medications within 14
days of study drug administration.
11. History of testing positive for human immunodeficiency virus (HIV) or known acquired
immunodeficiency syndrome (AIDS).
12. History of primary immunodeficiency.
13. History of active tuberculosis.
14. History of allogeneic stem cell transplantation or organ transplantation.
15. Autologous hematopoietic stem cell transplantation performed within 90 days prior to
the first dose of AK105.
16. History of gastrointestinal perforation and /or within 6 months prior to enrollment.
17. History of interstitial lung disease.
18. Patients with untreated chronic hepatitis B or with HBV DNA exceeding 500 IU/mL, or
with active hepatitis C should be excluded. Inactive HBsAg carriers, treated and
stable hepatitis B patients (HBV DNA < 500 IU/mL), or cured hepatitis C patients can
be enrolled. For patients with positive HCV antibody, they are eligible to participate
in the study only if the test result of HCV RNA is negative.
19. Major surgical procedure (as defined by the investigator) within 30 days prior to the
first dose of AK105 or still recovering from prior surgery. Local procedures (eg,
placement of a systemic port, core needle biopsy, and prostate biopsy) are allowed if
completed at least 24 hours prior to the administration of the first dose of study
treatment.
20. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated
drainage.
21. Active infections requiring systemic treatment.
22. Uncontrolled concurrent disease, including but not limited to, persistent or active
infection, symptomatic congestive heart failure (according to the New York heart
association functional class defined 3 or 4), out of control of high blood pressure,
unstable angina, arrhythmia, severe peptic ulcer or gastritis, activity, or mental
illness/social status which will limit the participants compliance requirements or
damage to the participants to provide written informed consent.
23. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to
National Cancer Institute's (NCI's) Common Terminology Criteria for Adverse Events
(CTCAE) (NCI CTCAE v4.03) Grade 0 or 1, or to levels dictated in the
inclusion/exclusion criteria with the exception of alopecia. Subjects with
irreversible toxicity that is not reasonably expected to be exacerbated by the study
drug may be included (eg, hearing loss) after consultation with the medical monitor.
Subjects with = Grade 2 neuropathy will be evaluated on a case-by-case basis after
consultation with the medical monitor.
24. Receipt of live or attenuated vaccination within 30 days prior to the first dose of
AK105, or plan to have live or attenuated vaccination during the study.
25. Known allergy or reaction to any component of the AK105 formulation.
26. History of severe allergic reaction to any other monoclonal antibodies.
27. Women who are pregnant or nursing.
28. Any condition that, in the opinion of the investigator, would interfere with
evaluation of the investigational product or interpretation of subject safety or study
results.
|
